The Effect and Mechanism of Fufang Banbianlian Injection in the Treatment of Mesangial Proliferative Glomerulonephritis
Jiakai Chang,Lingling Wu,Lifeng Tang,Fei Peng,Jiayi He,Huiming Ni,Jiaona Liu,Shuang Li,Shuwei Duan,Xiangmei Chen
DOI: https://doi.org/10.2174/0113862073272415231119133102
2024-01-08
Combinatorial Chemistry & High Throughput Screening
Abstract:Objective: Mesangial proliferative glomerulonephritis (MsPGN) is an important cause of chronic kidney disease. Abnormal proliferation of mesangial cells and immune-inflammatory response are its important pathological manifestations. Currently, there is no ideal treatment for this disease. Fufang Banbianlian Injection (FBI) has anti-inflammatory, antioxidant, and immuneenhancing effects, and is mostly used for the treatment of bronchitis, pneumonia, and respiratory tract infections in children. Methods: A rat model of MsPGN was established and treated with FBI. The efficacy was tested through pathological experiments and urine protein quantification. Network pharmacology methods were used to predict the signaling pathways and key proteins that exert the efficacy of FBI, and were screened through molecular docking experiments. The active substances that work were verified through cell experiments. Results: The results confirmed that intervention with FBI can inhibit the proliferation of glomerular cells and reduce the infiltration of macrophages, thereby reducing the pathological damage of rats with mesangial proliferative nephritis; it has been found to have an obvious therapeutic effect. Molecular docking results have shown kaempferol (Kae), the main component of FBI, to have a good affinity for key targets. The results of in vitro verification experiments showed that FBI and its active ingredient Kae may play a therapeutic role by regulating the NF-κB signaling pathway in mesangial cells, inhibiting its activation and the secretion of proinflammatory cytokines. Conclusion: Through network pharmacology, molecular docking, and experimental verification, it was confirmed that FBI and its active ingredient Kae can reduce the molecular mechanism of pathological damage of MsPGN by regulating the NF-κB signaling pathway and providing potential therapeutic drugs for the treatment of this disease. result: The results of in vivo experiments confirmed that intervention with Fufang Banbianlian Injection can inhibit the proliferation of glomerular cells and reduce the infiltration of macrophages, thereby reducing the pathological damage of rats with mesangial proliferative nephritis, and has an obvious therapeutic effect. A total of 43 active components of Fufang Banbianlian Injection, 96 compound Injection-disease targets, and Fufang Banbianlian Injection-Mesangial Proliferative Glomerulonephritis targets were screened by network pharmacology. The results mainly included cell migration, cell proliferation and oxidative stress. The signaling pathways obtained by KEGG enrichment analysis mainly included the NF-κB signaling pathway, PI3K-Akt signaling pathway and MAPK signaling pathway. Molecular docking results showed that kaempferol, the main component of Fufang Banbianlian Injection, had good affinity for key targets. The results of in vitro verification experiments showed that Fufang Banbianlian Injection and its active ingredient kaempferol may play a therapeutic role by regulating the NF-κB signaling pathway in mesangial cells, inhibiting its activation and the secretion of proinflammatory cytokines. conclusion: Through network pharmacology, molecular docking and experimental verification, it was confirmed that Fufang Banbianlian Injection and its active ingredient kaempferol can reduce the molecular mechanism of pathological damage of Mesangial Proliferative Glomerulonephritis by regulating the NF-κB signaling pathway and provide its clinical application. Basic research evidence.
pharmacology & pharmacy,biochemical research methods,chemistry, applied